County Press praised for its strong news coverage at Newspaper Awards
The Isle of Wight County Press was praised for its rich mix of stories and strong news coverage at the prestigious Newspaper Awards last night (Wednesday).
The paper was one of six shortlisted in the Best Local Weekly Newspaper category - with Newsquest sister paper the Impartial Reporter taking the prize.
The County Press was commended, with judges saying: "Celebrating 140 years in print, this paper continues to offer great value with its rich mix of stories and strong news coverage."
Gary Cullum, director of the awards, said print is still "a force to be reckoned with" and the mission remains unchanged despite the digital revolution transforming news.
CP editor Lori Little, front right, with Newsquest colleagues at the Newspaper Awards (Image: Isle of Wight County Press) CP editor Lori Little said: "We are all absolutely thrilled that the Isle of Wight County Press has been recognised by the industry as one of the best local weekly newspapers in the country.
"We're already the best-selling and we can say we're among the very best too.
"It is testament to our dedicated team of professionally trained reporters who go out and about in our community to meet people and tell their stories.
"We pack our 80-page newspaper with exclusives and interesting features, and we listen to all the feedback we are given.
"This year we've made huge design and layout changes to our print product.
"We've also put the IW County Press on the map... within the last week I've been flying the flag for the paper, and the Island, at both Buckingham Palace where I met the King and at Downing Street where I met the Prime Minister.
Read more: County Press editor invited to 10 Downing Street to meet the Prime Minister
Read more: County Press talks trusted news with the King at Buckingham Palace reception
"Thanks to everyone who buys the CP - you are directly contributing to the delivery of trusted news to the Island and keeping this heritage brand alive."
The Newspaper Awards was held at the London Hilton Bankside.
Online, we retain our position as the Island's biggest news website by quite some margin.
SimilarWeb showed in February we recorded 3.008 million page views when the second biggest website recorded 1.231 million.
Our visits for February were 1.789 million when the second biggest website recorded 925,817.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan
MELBOURNE, Australia and KYOTO, Japan, June 4, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that it has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company's global manufacturing strategy. TMS Yokohama will serve as a hub for commercial and clinical supply, and future research and development in the region. It expands Telix's global production network which includes in-house and partner facilities. Originally opened in 2018, the site comprises a cyclotron and multiple production hot cells and was designed and built by JFE Engineering Corporation (JFE) as the Contract Manufacturing Organization (CMO) for TLX250-CDx (Zircaix®[1], 89Zr-girentuximab) in Japan and China, including for the ZIRCON-CP study[2]. Taking over the lease and operational management of this facility will provide greater control over existing clinical supply with the possibility to expand production to other Telix investigational and future commercial products in the region, including Illuccix® (TLX591-CDx, 68Ga-PSMA-11) and Pixclara®1 (TLX101-CDx, 18F-floretyrosine) for Greater Tokyo, and TLX591 (177Lu rosopatamab tetraxetan) for the Asia Pacific region. Further, the Company plans to install Telix's ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, which it believes will facilitate standardized, high-efficiency and cost-effective production of commercially important medical isotopes. Darren Patti, Group Chief Operating Officer, Telix said, "We are pleased to announce Telix's first cyclotron facility in the Asia Pacific region, strategically located in Japan — the world's second-largest nuclear medicine market. TMS Yokohama enhances our capacity to meet growing demand in the region and supports our mission to provide patients with access to advanced diagnostic and therapeutic radiopharmaceuticals." About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[1], by the Australian Therapeutic Goods Administration (TGA)[2], by Health Canada[3], by the Brazilian Health Regulatory Agency (ANVISA)[4], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[5], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[6] and in multiple countries within the European Economic Area (EEA)[7] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[8]. TLX250-CDx, TLX101-CDx and TLX591 have not received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: [1] Telix ASX disclosure 20 December 2021. [2] Telix ASX disclosure 2 November 2021. [3] Telix ASX disclosure 14 October 2022. [4] Telix ASX disclosure 18 March 2025. [5] Telix ASX disclosure 13 February 2025. [6] Telix media release 29 April 2025. [7] Czech Republic, Denmark, Finland, Ireland, Luxembourg, Malta, the Netherlands, Norway and Sweden at time of release. [8] Telix ASX disclosure 17 January 2025. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited Sign in to access your portfolio
Yahoo
5 days ago
- Yahoo
ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP
Novartis is hoping that Scemblix (asciminib) will become the physician's first choice of therapy for chronic myeloid leukaemia in chronic phase (CML-CP) after it has shown to be more tolerable than the standard of care (SOC) in a Phase IIIb trial. Scemblix is a first-in-class STAMP inhibitor which received accelerated approval by the US Food and Drug Administration (FDA) in 2021 in previously treated CML in adult patients. On 29 October 2024, the FDA granted accelerated approval to the drug as a first-line therapy in CML-CP. Interim data presented at the American Society of Clinical Oncology (ASCO) 2025 meeting, held from 30 May to 3 June in Chicago, from the ongoing ASC4START (NCT05456191) study showed the drug met its primary endpoint of superior tolerability. In the study, 120 patients were randomised to receive either Scemblix 80mg daily or nilotinib 300mg twice daily, a SOC tyrosine kinase inhibitor (TKI), with the primary endpoint looking at treatment discontinuation due to adverse events (AEs) or treatment-related deaths. Patients were evaluated for an average of 9.7 months with this preliminary data cutoff happening after 50 trial-reported AEs. At this cutoff, 10.9% of patients on Scemblix had discontinued treatment compared with 17.3% of patients on nilotinib, achieving the primary endpoint with a cause-specific hazard ratio of 0.45. Novartis added that the study is ongoing with further analyses planned for tolerability and efficacy of Scemblix with a 65-event cut-off. It follows the ASC4FIRST study (NCT04971226) for efficacy in which Scemblix outperformed SOC TKI with a major molecular response (MMR) rate of 74.1% at week 96 compared with 52% for those on SOC TKIs after 96 weeks of treatment. The company hopes this additional tolerability data will support physician preference for Scemblix as a first-line therapy for patients with CML-CP. While the data may convince physicians, its ability to become SOC will depend on the agencies and payers said Dr. Andreas Hochhaus, principal investigator and director of the University Tumor Center (UTC) at the Jena University Hospital, Germany. Speaking to Clinical Trials Arena, Hochhaus said: 'We did this study to convince the agencies in different countries for reimbursement because SOC means you need reimbursement, and it's important to show all kinds of data and that means efficacy, but also tolerability. In CML, we have improved survival almost to the survival expectation of the normal population. Therefore, this cannot be improved anymore, so you need other endpoints such as quality of life and AEs..' "ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Yahoo
Canadian Pacific Kansas City price target raised to C$127 from C$119 at CIBC
CIBC analyst Kevin Chiang raised the firm's price target on Canadian Pacific Kansas City (CP) to C$127 from C$119 and keeps an Outperformer rating on the shares. The firm says it has seen improved sentiment across the freight transportation sector given the 90-day delay in the 145% tariffs on Chinese goods, along with the corresponding reduction on U.S. goods imported to China to 10%. This 'helps de-risk the outlook for the freight sector,' the analyst tells investors in a research note. As such, CIBC took up target multiples in the group. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CP: Disclaimer & DisclosureReport an Issue Canadian Pacific Kansas City price target raised to $90 from $82 at BofA Pershing Square takes new stake in Uber, converts Nike position to options Pershing Square takes new stake in Uber, exits Nike Canadian Pacific Kansas City: Strong Financial Performance and Strategic Positioning Justify Buy Rating CPKC Earnings Call: Strong Growth Amid Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
